GlassScriptPhysician profile
Michelle Wong
NPI 1316655996
$7,618.92
in general payments reported to CMS, 2019-2025
22 companies · $3,763 in 2025
The $3,763 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $869 · 2024: $2,987 · 2025: $3,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,366 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,365.93 |
| Education | $252.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,262.68 | 2023-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,033.12 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $741.05 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Ucb, INC. | $666.91 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $597.89 | 2023-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $572.41 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $545.04 | 2023-2025 | Benlysta |
| Lilly USA, LLC | $371.85 | 2023-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $353.94 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.36 | 2023-2025 | Ofev, Cyltezo, Jascayd |
| Astrazeneca Pharmaceuticals LP | $250.40 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $221.15 | 2023-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $188.55 | 2023-2025 | Lupkynis |
| Radius Health, INC. | $177.43 | 2024-2025 | Tymlos |
| Pfizer INC. | $91.65 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $74.64 | 2024 | Tyenne |
| Genzyme Corporation | $59.85 | 2025 | |
| Sobi, INC | $53.12 | 2024-2025 | |
| Octapharma USA, INC. | $24.26 | 2024 | Octagam Immune Globulin (Human) |
| Tonix Medicines, INC. | $21.46 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $19.31 | 2025 | |
| Depuy Synthes Sales INC. | $15.85 | 2025 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.